Trial Profile
Second phase II study of NRX-101 in patients with bipolar depression
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Jan 2017
Price :
$35
*
At a glance
- Drugs Cycloserine/lurasidone (Primary)
- Indications Bipolar depression
- Focus Therapeutic Use
- 06 Jan 2017 New trial record
- 04 Jan 2017 Results published in a NeuroRx media release.